Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus STERANE.
A-METHAPRED vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
100 mg orally every 12 hours
None Documented
None Documented
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid